STOMACH-SPECIFIC MUCOADHESIVE NANOPARTICLES AS A CONTROLLED RELEASE DRUG DELIVERY SYSTEM
In recent years scientific and technological advancement have been made in the rate controlled oral drug delivery system by overcoming physiological adversities, such as short gastric residence time (GRT) and unpredictable gastric emptying time (GET). So an interest increased towards novel dosage forms, that can retained in the stomach for a prolonged and predictable period of time. The concept of such novel dosage forms is to decrease the GI transit rate of the drug delivery system by attachment to the mucus layer, thereby increasing the overall time for drug absorption. A further advantage of such delivery systems is that the drug no longer must diffuse through the luminal contents in order to reach the mucosal epithelium. Various polymers have been used in the formulation of stomach specific mucoadhesive nanoparticles for drug delivery to increase therapeutic benefit, while minimizing side effects. Here we have discussed about concept of gastric emptying, absorption window, potential drug candidates, technological development evaluation and applications for stomach-specific mucoadhesive nanoparticles. Marketed products for oral nanoparticulate drug delivery systems are also discussed in this review.
Helliwell M. The use of bioadhesives in targeted delivery within the gastrointestinal tract. Adv Drug Delivery Rev 1987;11:221-51.
Gruber P, Longer MA, Robinson JR. Some biological issues in oral, controlled drug delivery. Adv Drug Delivery Rev 1987;1:1-18.
Wade A. (Ed.) Drug absorption. In: Pharmaceutical handbook, The Pharmaceutical Press, London, 1980;19:294-334.
Veillard M. Buccal and gastrointestinal drug delivery systems. In: Gurny R. and Junginger HE. (Eds.), Bioadhesion possibilities and future trends, Wissenschaftliche Verlagsgesellschaft, Stuttgart. 1990:124-39.
Robinson JR. Rationale of bioadhesion/ mucoadhesion. In: Gurny R. and Junginger HE. (Eds.), Bioadhesion possibilities and future trends, Wissenschaftliche Verlagsgesellschaft, Stuttgart. 1990:13-5.
Kumar R, Philip A. Gastroretentive dosage forms for prolonging gastric residence time. Int J Pharm Med 2007;21(2):157-71.
Kharia AA, Hiremath S et al., Gastro retentive drug delivery system: an overview. Indian Drugs 2011;48(05):7-15.
David AE, Zhang R et al., Mucoadhesive nanocomposite delivery system. US patent 20090232899 A1; 2009.
Deshpande AA, Rhodes CT et al., Development of a novel controlled release system for gastric retention. Drug Dev Ind Pharm 1996;22(6):105-13.
Singh BN, Kim KH. Floating drug delivery system- an approach to oral controlled drug delivery via gastric retention. J Control Release 2006;63:235-54.
Angela MacAdam. The effect of gastro-intestinal mucus on drug absorption. Adv Drug Delivery Rev 1993;11:201-20.
Dodou D, Breedveld P et al., Mucoadhesives in the gastrointestinal tract: revisiting the literature for novel applications. Eur J Pharm Biopharm 2005;60:1-16.
Shojaei AH, Berner B. Gastric retentive dosage forms. In: Li X, Jasti BS. (Eds.), Design of controlled release drug delivery systems. McGraw-Hill Companies, USA. 2006:173-201
Roy SK, Prabhakar B. Bioadhesive polymeric platforms for transmucosal drug delivery systems - a review. Trop J Pharm Res 2010;9(1):91-104.
Mohanraj VJ, Chen Y. Nanoparticles- A Review. Trop J Pharm Res 2006;5(1):561-73.
Hunter AC, Elsom J et al., Polymeric particulate technologies for oral drug delivery and targeting: a pathophysiological perspective. Nanomedicine 2012;8:S5-S20.
Desai PP, Date AA et al., Overcoming poor oral bioavailability using nanoparticle formulations - opportunities and limitations. Drug Discov Today Techno 2012;9(2):E87-95.
Mathiowitz E, Jacob JS et al., Biologically erodible microspheres as potential oral drug delivery system. Nature 1997;386:410-14.
Umamaheshwari RB, Ramteke S et al., Antiâ€“Helicobacter Pylori effect of mucoadhesive nanoparticles bearing amoxicillin in experimental gerbilâ€™s model. AAPS PharmSciTech 2004;5(2):1-9.
Katayama H, Nishimura T et al., Sustained release liquid preparation using sodium alginate for eradication of Helicobacter Pylori. Biol Pharm Bull 1999;22(1):55-60.
Liu Z, Lu W et al., In-vitro and in-vivo studies on mucoadhesive microspheres of amoxicillin. J Control Release 2005;102(1):135-44.
Jacob JS, Mathiowitz E et al., Controlled regional oral delivery. US patent 20060045865 A1; 2006.
Shishu, Gupta N et al., Stomach-specific drug delivery of 5-fluorouracil using floating alginate beads. AAPS PharmSciTech 2007;8(2):E1-E7.
Mitragotri S, Shen Z. Methods for oral drug delivery. US patent 20030017195; 2003.
Makhlof A, Werle M et al., A mucoadhesive nanoparticulate system for the simultaneous delivery of macromolecules and permeation enhancers to the intestinal mucosa. J Control Release 2011;149:81-8.
Suwannateep N, Banlunara W et al., Mucoadhesive curcumin nanospheres: Biological activity, adhesion to stomach mucosa and release of curcumin into the circulation. J Control Release 2011;151:176-82.
Irache JM, Huici M et al., Bioadhesive properties of Gantrez nanoparticles. Molecules 2005;10:126-45.
Arora S, Gupta S et al., Amoxicillin loaded chitosan - alginate polyelectrolyte complex nanoparticles as mucopenetrating delivery system for H. Pylori. Sci Pharm 2011;79:673-94.
Park K, Robinson JR. Bioadhesive polymers as platforms for oral-controlled drug delivery: method to study bioadhesion. Int J Pharm 19844;19:107-27.
Bhat PG, Flanagan DR et al., Drug binding to gastric mucus glycoproteins. Int J Pharm 1996;134:15-25.
Ponchel G, Montisci MJ et al., Mucoadhesion of colloidal particulate systems in the gastro-intestinal tract. Eur J Pharm Biopharm 1997;44:25-31.
Tur KM, Cheng HS et al., Use of bioadhesive polymer to improve the bioavailability of griseofulvin. Int J Pharm 1997;148:63-71.
Ponchel G, Irache JM. Specific and non-specific bioadhesive particulate systems for oral delivery to the gastrointestinal tract. Adv Drug Delivery Rev 1998;34:191-219.
Hillery AM. Microparticulate delivery systems: potential drug/vaccine carriers via mucosal routes. PSTT 1998;1(2):69-75.
Sakuma S, Sudo R et al., Mucoadhesion of polystyrene nanoparticles having surface hydrophilic polymeric chains in the gastrointestinal tract. Int J Pharm 1999;177:161-72.
Lehr CM. Lectin-mediated drug delivery: The second generation of bioadhesives. J Control Release 2000;65:19-29.
Pan Y, Li YJ et al., Bioadhesive polysaccharide in protein delivery system: chitosan nanoparticles improve the intestinal absorption of insulin in vivo. Int J Pharm 2002;249:139-47.
Muller RH, Jacobs C., Buparvaquone mucoadhesive nanosuspension: preparation, optimisation and long-term stability. Int J Pharm 2002;237:151-61.
Vasir JK, Tambwekar K et al., Bioadhesive microspheres as a controlled drug delivery system. Int J Pharm 2003;255:13-32.
Arbosa P, Campanero MA et al., Nanoparticles with specific bioadhesive properties to circumvent the pre-systemic degradation of fluorinated pyrimidines. J Control Release 2004;96:55-65.
Salman HH, Gamazo C et al., Salmonella like bioadhesive nanoparticles. J Control Release 2005;106:1-13.
Yao H, Xu L et al., A novel riboflavin gastro-mucoadhesive delivery system based on ion-exchange fiber. Int J Pharm 2008;364:21-6.
Madhav NVS, Shakya AK et al., Orotransmucosal drug delivery systems: A review. J Control Release 2009;140:2-11.
Moghaddam FA, Atyabi F et al., Preparation and in vitro evaluation of mucoadhesion and permeation enhancement of thiolated chitosan-pHEMA core-shell nanoparticles. Nanomedicine 2009; 5:208-15.
Tao Y, Lu Y et al., Development of mucoadhesive microspheres of acyclovir with enhanced bioavailability. Int J Pharm 2009; 378:30-36.
Dudhani AR, Kosaraju SL. Bioadhesive chitosan nanoparticles: Preparation and characterization. Carbohydr Polym 2010; 81:243-51.
Plapied L, Vandermeulen G et al., Bioadhesive nanoparticles of fungal chitosan for oral DNA delivery. Int J Pharm 2010; 398:210-18.
Meng J, Sturgis TF et al., Engineering tenofovir loaded chitosan nanoparticles to maximize microbicide mucoadhesion. Eur J Pharm Sci 2011;44:57-67.
Yadav VK, Kumar B et al., Design and evaluation of mucoadhesive microspheres of repaglinide for oral controlled release. Int J Drug Deliv 2011; 3:357-70.
Gaba P, Singh S et al., Galactomannan gum coated mucoadhesive microspheres of glipizide for treatment of type 2 diabetes mellitus: In vitro and in vivo evaluation. Saudi Pharm J 2011; 19:143-52.
Kammona O, Kiparissides C. Recent advances in nanocarrier-based mucosal delivery of biomolecules. J Control Release 2012; 161:781-94.
Ahmed HE, Kamel OA et al., Ammonium methacrylate unitâ€™s polymer content and their effect on acyclovir colloidal nanoparticles properties and bioavailability in human volunteers. Colloids Surf B Biointerfaces 2010; 75:398-404.
Bellare J, Banerjee R et al., Aspirin loaded albumin nanoparticles by coacervation: implications in drug delivery. Trends Bio Artif Organs 2012;18(2):203-11.
Tripathi A, Gupta R et al., PLGA nanoparticles of anti tubercular drug: drug loading and release studies of a water in-soluble drug. Int J Pharm Tech Res 2010;2:2116-23.
Ninan M. Development and evaluation of new sustained-release floating microspheres. Int J Pharm 2008;358:82-90.
Jahanshahi M, Babaei Z. Protein nanoparticle: A unique system as drug delivery vehicles. Afr J Biotechnol 2008;7(25):4926-34.
Amany OK, Gehanne AS. Preparation of intravenous stealthy acyclovir nanoparticles with increased mean residence time. AAPS PharmSciTech 2009;10(4):1427-36.
Khoshla R, Davis SS. The effect of polycarbophil on the gastric emptying of pellets, J Pharm Pharmacol 1987; 39:47-9.
Wirth M. Instrumental color measurement: method for judging the appearance of tablet. J Pharm Sci 1991; 80:1177-79.
Copyright (c) 2013 Mintage Journal of Pharmaceutical and Medical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.